Eagle Eye Corp is categorized under Pharmaceutical Manufacturing Plant Construction in Chicago, IL and active since 2012.
Eagle Eye Corp was established in 2012, and today employs 1 to 4, earning Unknown per year. This is a Pharmaceutical Manufacturing Plant Construction business, which does work in the B2B market, and is classified as a Pharmaceutical Manufacturing Plant Construction, under code number 9999900 by the NAICS.
If you are seeking more information, feel free to contact Cleothis Pounds at the company’s single location by writing to 7933 South Wolcott Avenue, Chicago, Illinois IL 60620 or by phoning (773) 633-2224. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Eagle Eye Corp |
| Contact Person: | Cleothis Pounds |
| Address: | 7933 South Wolcott Avenue, Chicago, Illinois 60620 |
| Phone Number: | (773) 633-2224 |
| Annual Revenue (USD): | Unknown |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Pharmaceutical Manufacturing Plant Construction |
| SIC Code: | 1541 |
| NAICS Code: | 9999900 |
| Share This Business: |
Eagle Eye Corp was started in 2012 to provide professional Pharmaceutical Manufacturing Plant Construction under the SIC code 1541 and NAICS code 9999900. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Cleothis Pounds for inquiries that concern Eagle Eye Corp by calling the company number (773) 633-2224, as your correspondence is most welcome. Additionally, the physical location of the single location of Eagle Eye Corp can be found at the coordinates 41.749425,-87.67055 as well as the street address 7933 South Wolcott Avenue in Chicago, Illinois 60620.
For its online presence, you may visit Eagle Eye Corp’s website at and engage with its social media outlets through on Twitter and on Facebook.